Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Othman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht...
https://pubmed.ncbi.nlm.nih.gov/38071379/Actively Recruiting
Led by German CLL Study Group · Updated on 2026-08-20
83
Participants Needed
11
Research Sites
N/A
Total Duration
Researchers are evaluating the effectiveness and safety of combining zanubrutinib, a BTK inhibitor, with tislelizumab, a PD-1 inhibitor, for treating patients with Richter Transformation RT, a serious complication in chronic lymphocytic leukemia CLL. RT is challenging to manage, with poor prognosis and limited success from conventional chemoimmunotherapy. This trial aims to explore new treatment options due to the urgent need for better therapies. The study involves two treatment groups one receiving tislelizumab plus zanubrutinib, and the other receiving tislelizumab, zanubrutinib, and sonrotoclax, a Bcl-2 inhibitor. Participants undergo induction with six 21-day cycles of assigned treatments, followed by six consolidation cycles on the same schedule. Those who respond continue on maintenance therapy with their assigned drugs every three weeks until disease progression, intolerance, or receiving stem cell transplantation. Participants will be closely monitored throughout the study, which lasts up to 15 months, with assessments including response rates after induction and consolidation, progression-free and overall survival, time to next treatment, and duration of response. Safety will be tracked by recording adverse events. The trial includes laboratory tests, imaging, and clinical evaluations to measure treatment effects and tolerability over time.
CONDITIONS
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation
B
Barbara Eichhorst, Prof.
O
Othman Al-Sawaf, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
German CLL Study Group
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 18 weeks
Participants receive six 21-day cycles of treatment with either tislelizumab plus zanubrutinib or tislelizumab plus zanubrutinib and sonrotoclax.
Every 3 weeks for 6 cycles
Duration - Approximately 18 weeks
Participants receive six additional 21-day cycles of the assigned treatment combination.
Every 3 weeks for 6 cycles
Duration - Until disease progression or intolerance
Participants who respond to therapy continue maintenance treatment with their assigned drugs every three weeks until disease progression, intolerance, or stem cell transplantation.
Every 3 weeks
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Othman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht...
https://pubmed.ncbi.nlm.nih.gov/38071379/German CLL Study Group
Lead Sponsor